Key points from article :
Medical Microinstruments has secured $110 million to commercialize its Symani system.
Wristed instruments small enough to help surgeons suture the most delicate blood vessels and tissues.
Fund to support collecting clinical evidence and establish new hospital partnerships.
"This support builds on our confidence in a new, less invasive solution for open surgery,” - MMI CEO Mark Toland
Upon receiving CE mark approval in Europe, MMI now plans to expand its reach in the U.S. and the Asia Pacific region.
Symani's robotic arms mimic human hands with tremor reduction.
It can assist in open soft-tissue procedures, lymphatic surgery and trauma replantations.
Predicts rise in Symani’s eligible procedures, from 3 to 22 million per year by 2028, pending device development and future regulatory green lights.
